To provide nephrologists, cardiologists, primary care physicians, and clinical pharmacists with up-to-date information on the prevention of cardiovascular disease in patients with kidney disease.
This activity is designed for nephrologists, cardiologists, primary care physicians, advanced practice nurses, and clinical pharmacists. No prerequisites required.
The Johns Hopkins University School of Medicine and the University of Tennessee College of Pharmacy take responsibility for the content, quality, and scientific integrity of this CE activity. At the conclusion of this activity, participants should be able to:
- Provide an overview of the relationship between chronic kidney disease (CKD) and cardiovascular disease (CVD).
- Discuss strategies for identifying traditional and nontraditional CVD risk factors with specific focus on the American Heart Associations Statement on kidney disease as a risk factor for the development of CVD.
- Develop and implement practical protocols for the prevention and treatment of CVD in patients with CKD, using information from recently completed and ongoing clinical trials.
- Explain the risks and benefits of treating anemia in patients with CKD who either have CVD or are at risk fir developing it, including discussion of the National Kidney Foundation’s Clinical Practice Guidelines for Anemia of CKD.
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The University of Tennessee College of Pharmacy is approved by the Accreditation Council for Pharmacy Education as a provider of continuing pharmaceutical education.
CREDIT DESIGNATION STATEMENT
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 2 category 1 credits toward the AMA Physician’s Recognition Award.
This program is approved for 2 hours (0.2 CEUs) and is cosponsored by the University of Tennessee College of Pharmacy, which is approved by the American Council on Pharmacy Education as a provider of continuing pharmaceutical education. A statement of CE credit will be mailed within 4 weeks of successful completion and evaluation of the program. ACPE program #064-999-05-229-H01.
Each participant should claim only those credits that he/she actually spent in the activity.
The estimated time to complete this educational activity: 2 hours.
Release date: July 15, 2005. Expiration date: July 15, 2007.
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of the Johns Hopkins University School of Medicine, and the University of Tennessee College of Pharmacy names implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.
This program is supported by an educational grant from Amgen Inc.